Ironwood Pharmaceuticals, Inc. (IRWD)

8,12 +0,01 (+0,12 %) À la clôture : 04:00PM EDT

Ironwood Pharmaceuticals, Inc.

100 Summer Street
Suite 2300
Boston, MA 02110
United States
617 621 7722
https://www.ironwoodpharma.com

Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - Specialty & Generic
Employés à temps plein: 267

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Thomas A. McCourt	CEO & Director	1,61M	46,82k	1957
Mr. Sravan Kumar Emany	Senior VP, Principal Financial Officer & CFO	913,88k	S.O.	1978
Mr. John Minardo	Senior VP, Chief Legal Officer & Secretary	814,41k	S.O.	1976
Dr. Michael Shetzline M.D., Ph.D.	Chief Medical Officer, Senior VP and Head of Research & Drug Development	860,45k	S.O.	1959
Mr. Andrew Davis	Senior VP & Chief Business Officer	824,36k	S.O.	1987
Mr. Ronald Silver	Corporate Controller & Principal Accounting Officer	S.O.	S.O.	1983
Mr. Marcel Moulaison	Vice President of Technical Operations	S.O.	S.O.	S.O.
Greg Martini	Vice President of Strategic Finance & Investor Relations	S.O.	S.O.	S.O.
Ms. Beth Calitri	Head of Corporate Communications & Media Relations	S.O.	S.O.	S.O.
Mr. Mike Nanfito	Vice President of Sales & Sales Excellence	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Ironwood Pharmaceuticals, Inc. en date du 1 mai 2024 est 4. Les scores principaux sont Audit : 6; Société : 3; Droits des actionnaires : 6; Compensation : 1.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.